NINDS Direct Phase II SBIR Grants to Support Exploratory Clinical Trials (R44) -- AIDS

Funding Agency:
National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory clinical trial applications to the newly authorized Direct-to-Phase II SBIR grant mechanism.  The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, R&D that is characteristic of Phase-I (R43) SBIR projects.  The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type R&D, to expand R&D opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization. 

Deadlines:

  • Letter of Intent: 30 days before each application due date.
  • R44 Due Dates: Apr. 5, Aug. 5, Dec. 5
  • AIDS Due Dates: Jan. 7, May 7, Sep. 7

PAR-14-265 Expiration Date January 8, 2017

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

Funding Type

Grant

Eligibility

Faculty

Category

Engineering and Physical Sciences
Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

May 7, 2017